ArticleTranslational cancer research2025
Development and validation of a novel prognostic signature for osteosarcoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteosarcoma (OS) is a primary malignant bone tumor known for its aggressive nature and high potential for metastasis, primarily impacting adolescents and young adults. Few studies have focused on discovering gene signatures that effectively guide treatment strategies and predict outcomes in OS. The study aimed to create a prognostic model to predict OS patient survival. Methods: Candidate genes were identified by intersecting genes from survival analyses of two patient datasets. Unsupervised consensus clustering was employed with these candidate genes to investigate potential tumor types. Following this, a gene signature was developed and validated within one of the datasets. Finally, the immune microenvironment was assessed using the CIBERSORT and ESTIMATE algorithms. Results: A total of 123 candidate genes were identified, and samples from the Gene Expression Omnibus (GEO) dataset were subsequently partitioned into two clusters through unsupervised cluster analysis utilizing these candidate genes. Univariate Cox regression was employed to select 46 genes, from which a ten-gene signature was developed using the least absolute shrinkage and selection operator (LASSO) regression to predict the prognosis of OS. The resulting novel gene signature demonstrated significant predictive accuracy for the overall survival of patients with OS. Conclusions: In conclusion, we have discovered a ten-gene signature that serves as a new prognostic predictor for OS patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.